Your browser is no longer supported. Please, upgrade your browser.
MYL Mylan N.V. daily Stock Chart
Mylan N.V.
IndexS&P 500 P/E44.94 EPS (ttm)0.44 Insider Own0.30% Shs Outstand529.16M Perf Week-11.41%
Market Cap10.39B Forward P/E4.31 EPS next Y4.55 Insider Trans-0.72% Shs Float509.86M Perf Month-26.52%
Income225.90M PEG9.36 EPS next Q0.95 Inst Own86.90% Short Float1.72% Perf Quarter-38.32%
Sales11.24B P/S0.92 EPS this Y-57.40% Inst Trans0.23% Short Ratio1.23 Perf Half Y-45.08%
Book/sh23.09 P/B0.85 EPS next Y5.84% ROA0.70% Target Price31.94 Perf Year-49.87%
Cash/sh0.55 P/C35.65 EPS next 5Y4.80% ROE2.00% 52W Range19.40 - 42.50 Perf YTD-28.32%
Dividend- P/FCF7.39 EPS past 5Y-16.70% ROI3.50% 52W High-53.79% Beta1.51
Dividend %- Quick Ratio0.90 Sales past 5Y10.60% Gross Margin39.80% 52W Low1.24% ATR1.07
Employees35000 Current Ratio1.50 Sales Q/Q-7.00% Oper. Margin6.80% RSI (14)24.13 Volatility4.08% 4.41%
OptionableYes Debt/Eq1.16 EPS Q/Q-128.80% Profit Margin2.10% Rel Volume0.73 Prev Close20.21
ShortableYes LT Debt/Eq1.10 EarningsMay 07 BMO Payout0.00% Avg Volume7.14M Price19.64
Recom2.10 SMA20-20.60% SMA50-25.94% SMA200-37.74% Volume5,230,222 Change-2.82%
May-08-19Downgrade Wells Fargo Outperform → Market Perform $33 → $22
Mar-20-19Initiated SunTrust Buy $35
Mar-07-19Resumed UBS Neutral $31
Mar-06-19Upgrade Morgan Stanley Equal-Weight → Overweight $35
Feb-27-19Downgrade Bernstein Outperform → Mkt Perform $33
Jan-23-19Downgrade UBS Buy → Neutral
Nov-15-18Upgrade Argus Hold → Buy
Nov-06-18Upgrade BofA/Merrill Neutral → Buy
Oct-09-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-05-18Downgrade Mizuho Buy → Neutral
Aug-24-18Upgrade Evercore ISI In-line → Outperform
Aug-13-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Mar-15-18Reiterated Mizuho Buy $45 → $51
Mar-06-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-25-18Reiterated Susquehanna Positive $47 → $55
Jan-04-18Reiterated Citigroup Buy $48 → $58
Jan-03-18Initiated Leerink Partners Mkt Perform $44
Dec-12-17Initiated Guggenheim Buy $59
Nov-07-17Reiterated RBC Capital Mkts Sector Perform $32 → $37
May-18-19 10:45AM  Mylan Presents Equivalence and Device Usability Data on Wixela Inhub Compared to Advair Diskus® at American Thoracic Society International Conference PR Newswire
May-17-19 08:00AM  Mylan to Host Investor Day on July 31, 2019 in New York City PR Newswire
May-16-19 08:00AM  Generic Drugs Are Stabilizing Can They Survive An Antitrust Scandal? Investor's Business Daily
May-15-19 05:01PM  Mylan and Biocon to Present Final Overall Survival Data for Ogivri (trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
11:47AM  Teva Hits Fibonacci Support on Concerns Over Lawsuit Investopedia
10:34AM  Here are the most and least volatile stocks since Trump ramped up trade conflict MarketWatch
10:30AM  Mylan's stock falls toward 7 1/2-year low; credit rating now in danger of downgrade to 'junk' at Fitch MarketWatch
09:24AM  The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer Zacks
07:46AM  AbbVie Settles Humira Litigation With Boehringer Ingelheim Zacks
May-14-19 04:00PM  There's misinformation out there on generic drugs: Association of Accessible Medicines CEO CNBC Videos
10:17AM  Here's Why Generic-Drug Manufacturers Were Down Monday Motley Fool
09:18AM  Generic Drugmakers Face Antitrust Suit Alleging Price Fixing Zacks
May-13-19 05:30PM  The Dow Plunges 617 Points Because China Is Hitting Back With Retaliatory Tariffs -9.43%
04:48PM  Here are Mondays worst stock-market performers as U.S.-China trade dispute escalates MarketWatch
04:41PM  Teva, 19 other drug companies accused of inflating drug prices Yahoo Finance Video
02:38PM  Drug price fixing allegation may be increasingly problematic for makers: Analyst CNBC Videos
02:10PM  Mylan Call Options Hot as Stock Hits New Low Schaeffer's Investment Research
12:42PM  Forty-four states accuse Teva Pharmaceutical of inflating drug prices CNBC Videos
11:30AM  2 Drug Stocks to Buy as Health Care Suffers, According to JPMorgan
10:00AM  Stocks Dive As China Trade War Worsens; Teva, Mylan Tanks On Lawsuits Investor's Business Daily
May-12-19 11:00PM  US generic drug companies hit by price-fixing claims Financial Times
May-11-19 12:39PM  This will likely end badly: Analysts react to Mylans revenue miss and earnings call MarketWatch
May-10-19 09:45AM  Mylan Expands Oncology Portfolio with Launch of Generic Tarceva® Tablets PR Newswire
08:00AM  Mylan to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference PR Newswire
May-09-19 04:09PM  Mylan Stock Jumps On Rumored Bid After Lackluster First Quarter Investor's Business Daily
May-08-19 11:44AM  Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates Zacks
09:30AM  Company News For May 8, 2019 Zacks
08:02AM  Here are the biggest analyst calls of the day: Pinterest, US Steel, Mylan & more CNBC
07:34AM  3 Big Stock Charts for Wednesday:, DISH Network and F5 Networks InvestorPlace
07:00AM  Market Morning: Mylan Massacre, Futures Dither, Meatless McDonalds, Uber Drivers Bash Greed, Want More Money Market Exclusive
02:16AM  Mylan/generic pharma: from heyday to mayday Financial Times
May-07-19 09:43PM  Edited Transcript of MYL earnings conference call or presentation 7-May-19 2:00pm GMT Thomson Reuters StreetEvents -23.81%
05:09PM  The Dow Slumped 473 Points Because No One Wins a Trade War
04:58PM  AIG and SolarEdge rise while Mylan and Phibro fall Associated Press
04:32PM  Allergan Fended Off Botox Rivalries In The First Quarter But Can It Last? Investor's Business Daily
04:31PM  Mylan Suffers Biggest Drop in Almost Two Decades Amid Drug Pain Bloomberg
04:30PM  US STOCKS-Wall Street slides as U.S.-China trade fears rise Reuters
04:23PM  Mylan N.V. (MYL) Q1 2019 Earnings Call Transcript Motley Fool
03:21PM  Epipen Parent's Faceplant Is a Cautionary Tale for Botox Maker Bloomberg
03:04PM  Mylan Beats Estimates but Gets Slammed on Guidance Investopedia
03:00PM  Mylan's Struggles Continue in the First Quarter Motley Fool
02:59PM  US STOCKS-Wall Street extends decline as China trade worries mount Reuters
01:55PM  SeaWorld looks to Big Bird for help, Lyft drives toward earnings debut MarketWatch
01:51PM  Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss Zacks
01:35PM  Mylan notified that several states intend to file new complaint alleging anticompetitive conduct MarketWatch
01:30PM  'Near term' conclusion for Mylan strategic review American City Business Journals
01:15PM  Stocks making the biggest moves midday: Beyond Meat, Boeing, Mylan & more CNBC
01:04PM  Mylan Shares Tumble on Disappointing Revenue
12:57PM  US STOCKS-Wall Street extends fall as U.S-China trade worries mount Reuters
12:45PM  Mylan Tanks After First-Quarter Revenue Misses Estimates
12:29PM  Mylan gives no clear view on strategic options, shares plunge 17 percent Reuters
11:45AM  US STOCKS-Wall Street plunges on heightening U.S.-China trade worries Reuters
11:44AM  Why Mylan Stock Is Sinking Today Motley Fool
10:23AM  US STOCKS-Wall Street declines on U.S.-China trade tensions Reuters
09:45AM  Mylan (MYL) Surpasses Q1 Earnings Estimates Zacks
08:58AM  Mylan shares down 4.5% after drugmaker misses on revenue MarketWatch
08:42AM  Mylan: 1Q Earnings Snapshot Associated Press
08:30AM  Mylan Reports First Quarter 2019 Results and Reaffirms 2019 Guidance PR Newswire
04:36AM  Mylan Earnings Beat, Revenue Misses In Q1
May-06-19 04:17PM  Mylan reports first-quarter earnings on Tuesday. Heres what to expect MarketWatch
03:56PM  Mylan Expected to Earn 79 Cents a Share
08:13AM  3 Big Stock Charts for Monday: American Airlines Group, Mylan and Celgene InvestorPlace
May-03-19 05:22PM  Mylan (MYL) to Report Q1 Earnings: What's in the Offing? Zacks
08:36AM  Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall Zacks
May-02-19 11:44AM  Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1 Zacks
09:16AM  Glaxo (GSK) Beats on Q1 Earnings & Sales, Shingrix Impresses Zacks
May-01-19 09:05AM  Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure Zacks
Apr-30-19 10:32AM  Earnings Preview: Mylan (MYL) Q1 Earnings Expected to Decline Zacks
Apr-29-19 09:43AM  Teva (TEVA) to Report Q1 Earnings: What's in the Cards? Zacks
Apr-27-19 11:29AM  Biosimilar competition to AbbVies Humira is eroding profits, but company says it has confidence in pipeline MarketWatch
Apr-26-19 07:30AM  Mylan to Release First Quarter 2019 Financial Results on May 7, 2019 PR Newswire
Apr-25-19 08:08AM  AbbVie stock up 2% after earnings beat and raised outlook MarketWatch
Apr-24-19 01:50PM  AbbVie and Bristol-Myers Squibb will report first-quarter earnings on Thursday. Heres what to expect MarketWatch
Apr-18-19 08:00AM  TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis (TB) PR Newswire
Apr-16-19 02:04PM  Recordati to seek Canadian approval for kidney disease drug Reuters
11:41AM  Allergan Falls as Supreme Court Dismisses Restasis Litigation Zacks
Apr-15-19 09:46AM  U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents Reuters
Apr-14-19 12:15PM  Stocks That Fell to 3-Year Lows in the Week of April 12
Apr-11-19 10:04AM  Acorda to Gain From Inbrija Sales and Neurological Pipeline Zacks
Apr-03-19 11:00AM  Striving to Create Better Health for a Better World: Mylan's Global Social Responsibility 2018 Progress Report Now Available PR Newswire
Apr-01-19 12:27PM  Heres What Hedge Funds Think About Mylan N.V. (MYL) Insider Monkey
07:02AM  BMOs Got A Point About Teva Stock, But Are Investors Willing To Listen? InvestorPlace
Mar-28-19 09:30AM  Mylan (MYL) Up 8.6% Since Last Earnings Report: Can It Continue? Zacks
08:32AM  Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL) Zacks
Mar-22-19 01:36PM  Fed Up with Record of Earnings Misguidance, Investors Shun Mylan Bloomberg
08:44AM  Biogen stock downgraded to neutral from buy at UBS MarketWatch
Mar-20-19 10:43AM  Glaxo Presents Encouraging Data on Endometrial Cancer Drug Zacks
Mar-18-19 02:34PM  Mylan voluntarily recalls two lots of its levoleucovorin injection MarketWatch
12:48PM  Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter PR Newswire
08:00AM  Mapi Pharma Receives Government of Israel Funding for the Establishment of a Finished Dosage Form Facility for the Manufacturing of GA Depot Pharmaceuticals GlobeNewswire
Mar-14-19 03:12PM  5 Undervalued Stocks to Invest In InvestorPlace
12:27PM  Investors Are Paying the Price as Drugmakers Flood Bond Market Bloomberg
11:01AM  Insys Plunges on Auditor's Concern About Insufficient Funds Zacks
Mar-13-19 01:13PM  SEC Closes Probe Into Mylan's Real-Estate Dealings with Former Director The Wall Street Journal
Mar-12-19 03:46PM  FDA approves generic valsartan amid drug shortage Reuters
Mar-08-19 11:39AM  Why Biggest Valuation Gap In 70 Years Is Buying Opportunity Investopedia
Mar-07-19 03:00PM  SBP, Mylan Present Keys to Hurricane Maria Survivor in Welcome Home Party -- Courtesy of $1M Pledge from the Mylan Charitable Foundation PR Newswire
02:14PM  Biotech shares continue to fall on FDA uncertainty CNBC
07:25AM  New Research: Key Drivers of Growth for Toll Brothers, Mylan N.V, Eldorado Resorts, Sinclair Broadcast Group, Eldorado Gold, and Pegasystems Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-06-19 08:59AM  US STOCKS-Wall St set for muted open due to lack of fresh catalysts Reuters
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; TB Alliance; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gallagher Daniel Martin JrChief Legal OfficerApr 01Option Exercise0.008,515021,133Apr 03 06:00 PM
Campbell PaulSee RemarksMar 04Sale27.5011,533317,14324,137Mar 05 06:15 PM
BRESCH HEATHER MChief Executive OfficerMar 03Option Exercise0.0020,1420394,503Mar 05 06:06 PM
Gallagher Daniel Martin JrChief Legal OfficerMar 03Option Exercise0.008,218016,567Mar 05 06:09 PM
Mauro AnthonyChief Commercial OfficerMar 03Option Exercise0.005,534098,537Mar 05 06:11 PM
Malik RajivPresidentMar 03Option Exercise0.0012,3950275,388Mar 05 06:11 PM
Parks Kenneth ScottChief Financial OfficerMar 03Option Exercise0.003,984016,853Mar 05 06:13 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002190599Mar 05 06:15 PM
Campbell PaulSee RemarksMar 03Option Exercise0.00830024,493Mar 05 06:15 PM
Campbell PaulSee RemarksMar 02Option Exercise0.001670437Mar 05 06:15 PM
Campbell PaulSee RemarksMar 02Option Exercise0.001,980024,540Mar 05 06:15 PM
Parks Kenneth ScottChief Financial OfficerMar 02Option Exercise0.006,103015,541Mar 05 06:13 PM
Malik RajivPresidentMar 02Option Exercise0.0014,6450269,457Mar 05 06:11 PM
Mauro AnthonyChief Commercial OfficerMar 02Option Exercise0.006,103095,657Mar 05 06:11 PM
Gallagher Daniel Martin JrChief Legal OfficerMar 02Option Exercise0.007,811012,093Mar 05 06:09 PM
BRESCH HEATHER MChief Executive OfficerMar 02Option Exercise0.0022,2120384,223Mar 05 06:06 PM
Vollebregt Sjoerd SDirectorMar 02Option Exercise0.004,02808,258Mar 05 06:33 PM
VANDERVEEN RANDALL LDirectorMar 02Option Exercise0.004,028045,845Mar 05 06:30 PM
van der Meer Mohr PaulineDirectorMar 02Option Exercise0.004,56604,566Mar 05 06:27 PM
PARRISH MARK WDirectorMar 02Option Exercise0.004,028041,423Mar 05 06:25 PM
KORMAN HARRYDirectorMar 02Option Exercise0.004,566024,816Mar 05 06:23 PM
HIGGINS MELINA EDirectorMar 02Option Exercise0.004,028013,120Mar 05 06:22 PM
DIMICK NEIL FDirectorMar 02Option Exercise0.004,028048,645Mar 05 06:21 PM
Lyons Dillon JoEllenDirectorMar 02Option Exercise0.004,028013,667Mar 05 06:20 PM
Cindrich Robert JDirectorMar 02Option Exercise0.004,028023,107Mar 05 06:16 PM
Malik RajivPresidentFeb 19Option Exercise0.0014,5890584,940Feb 21 06:01 PM
Parks Kenneth ScottChief Financial OfficerFeb 19Option Exercise0.004,837011,550Feb 21 06:00 PM
BRESCH HEATHER MChief Executive OfficerFeb 19Option Exercise0.0025,2870751,359Feb 21 06:00 PM
Campbell PaulSee RemarksFeb 19Option Exercise0.001,216023,157Feb 21 06:00 PM
Mauro AnthonyChief Commercial OfficerFeb 19Option Exercise0.007,9430160,520Feb 21 06:00 PM
Malik RajivPresidentFeb 17Option Exercise0.0022,0240579,185Feb 20 06:02 PM
Parks Kenneth ScottChief Financial OfficerFeb 17Option Exercise0.002,14907,733Feb 20 06:00 PM
Campbell PaulSee RemarksFeb 17Option Exercise0.00540022,207Feb 20 06:00 PM
Mauro AnthonyChief Commercial OfficerFeb 17Option Exercise0.009,0150156,699Feb 20 05:00 PM
BRESCH HEATHER MChief Executive OfficerFeb 17Option Exercise0.0037,0940742,601Feb 20 05:01 PM
CAMERON WENDYDirectorJun 29Option Exercise0.004,028076,735Jul 03 04:35 PM